Shares of clinical-stage company Bellerophon Therapeutics (NASDAQ:BLPH) are soaring high today after the U.S. Food and Drug Administration (FDA) agreed to a reduction in the size of BLPH’s Phase 3 study of INOpulse for treating fibrotic interstitial lung disease (fiLD).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The data monitoring committee of the study supported lowering the study size to 140 from 300 and the change does not affect the trial’s principal objective or endpoints.
The company expects to complete enrolment in Q1 2023 with top-line data expected in Q3 2023.
Is BLPH a Good Stock to Buy?
Impressively, the Street has a Moderate Buy consensus rating on the stock alongside an average price target of $30 which implies a massive 2358.81% potential upside in the stock.
Read full Disclosure
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue